Table 2.
Micropaticles at Baseline and After Immunotherapy in iOR Group and iPD Group.
| iOR(n = 32) | iPD(n = 18) | P | |
|---|---|---|---|
| Total MPs, events/μL | |||
| At baseline | 2368.0[1618.5,3773.5] | 2416.0[1256.5.3630.5] | 0.808# |
| After immunotherapy | 1763.0[1207.0,3180.0] | 3590.0[1492.0,4995.0] | 0.026# |
| P | 0.248# | 0.134# | |
| PMPs, events/μL | |||
| At baseline | 110.0[60.5,177.5] | 141.5[90.75,244.5] | 0.148# |
| After immunotherapy | 52.0[22.5,108.5] | 201.5[90.5,298.5] | <0.0001# |
| P | 0.002# | 0.815# | |
| T-LyMPs, events/μL | |||
| At baseline | 197.5[69.25,308.75] | 225.5[135.75,309.25] | 0.511# |
| Afterimmunotherapy | 121.5[61.75,219.50] | 184.5[118.25,340.25] | 0.048# |
| P | 0.222# | 0.767# |
MPs, micropaticles; PMPs, Platelet-derived micropaticles; T-LyMPs, T-lymphocyte-derived micropaticles.
#Mann-Whitney U test.